Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma
This study is one monocentric, single-arm, open, phase Ⅱ clinical study to evaluate the
safety and efficacy of Toripalimab monoclonal injection (Tuo Yi) combined with axitinib
tablet (Inlyta®) as neoadjuvant therapy for localized mucosal melanoma.
Primary objective: To evaluate pathological complete response (pCR) rate of Toripalimab
combined with axitinib as neoadjuvant therapy for localized mucosal melanoma.
The subjects will receive Toripalimab and Axitinib combined therapy after enrollment, and
receive operation 2 weeks after the last dose of Axitinib. Toripalimab will be given for a
total of 4 cycles (8 weeks), whereas Axitinib will...